Want to see IN:GLENMARK full AI Analyst Report?
Top Page
Glenmark Pharmaceuticals Limited
(GLENMARK)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹2,643.00
▲(27.93% Upside)
Action:Reiterated
Date:06/02/26
The score is driven primarily by improved financial performance (profitability rebound and a significantly de-risked balance sheet), offset by historical earnings/cash-flow volatility. Technicals are mixed/neutral, and valuation is a key headwind due to the high P/E and minimal dividend yield.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates Glenmark is growing its commercial scale across branded, generic and API businesses. Continued top-line progress can support operating leverage and provide a broader base for future product launches and therapeutic-area growth.
Negative Factors
Earnings Volatility
Large earnings swings indicate that recent profitability has not yet proven consistent through business or product-cycle changes. This reduces earnings predictability and makes it harder to assess the durability of margins and sustainable returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates Glenmark is growing its commercial scale across branded, generic and API businesses. Continued top-line progress can support operating leverage and provide a broader base for future product launches and therapeutic-area growth.
Read all positive factors
Glenmark Pharmaceuticals Limited (GLENMARK) vs. iShares MSCI India ETF (INDA)
Market Cap
₹695.46B
Dividend Yield0.2%
Average Volume (3M)20.21K
Price to Earnings (P/E)38.6
Beta (1Y)0.53
Revenue Growth32.94%
EPS Growth138.54%
CountryIN
Employees16,946
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)48.26
Shares Outstanding282,224,670
10 Day Avg. Volume27,532
30 Day Avg. Volume20,207
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.72
Price to Sales (P/S)3.54
P/FCF Ratio30.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)82.23
Revenue Forecast (FY)₹167.88B
Glenmark Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, L...
How the Company Makes Money
Glenmark makes money primarily by selling pharmaceutical formulations (finished dosage medicines) and, to a lesser extent, APIs. Its revenue model is product-sales driven, with earnings generated when it supplies medicines to healthcare channels (...
Glenmark Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
80
Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 169.83B | 133.63B | 126.45B | 116.56B | 123.05B |
| Gross Profit | 80.84B | 88.38B | 80.66B | 72.45B | 77.57B |
| EBITDA | 27.67B | 21.68B | 18.30B | 14.29B | 19.12B |
| Net Income | 13.62B | 10.47B | -15.02B | 2.97B | 9.42B |
Balance Sheet | |||||
| Total Assets | 199.08B | 160.50B | 143.59B | 193.72B | 170.83B |
| Cash, Cash Equivalents and Short-Term Investments | 14.01B | 17.12B | 16.64B | 11.73B | 14.43B |
| Total Debt | 5.94B | 24.73B | 12.31B | 46.08B | 39.62B |
| Total Liabilities | 93.96B | 72.00B | 65.11B | 95.32B | 76.45B |
| Stockholders Equity | 105.12B | 88.49B | 78.48B | 94.74B | 90.87B |
Cash Flow | |||||
| Free Cash Flow | 19.41B | -15.77B | -11.64B | 176.29M | 3.19B |
| Operating Cash Flow | 32.99B | -8.28B | -2.65B | 6.25B | 11.09B |
| Investing Cash Flow | -13.25B | 20.94M | 45.44B | -5.28B | -3.33B |
| Financing Cash Flow | -25.21B | 7.87B | -39.06B | -774.56M | -5.20B |
Glenmark Pharmaceuticals Limited Technical Analysis
Positive
2065.95
Price Trends
2278.00
Positive
2273.14
Positive
2146.91
Positive
Market Momentum
59.99
Negative
62.44
Neutral
74.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLENMARK, the sentiment is Positive. The current price of 2065.95 is below the 20-day moving average (MA) of 2357.99, below the 50-day MA of 2278.00, and below the 200-day MA of 2146.91, indicating a bullish trend. The MACD of 59.99 indicates Negative momentum. The RSI at 62.44 is Neutral, neither overbought nor oversold. The STOCH value of 74.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLENMARK.
Glenmark Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹976.93B | 29.12 | ― | 0.69% | -0.92% | -41.75% | |
69 Neutral | ₹968.36B | 25.75 | ― | 0.26% | 9.09% | 9.61% | |
69 Neutral | ₹983.06B | 17.81 | ― | 0.76% | 28.19% | 49.25% | |
69 Neutral | ₹4.63T | 38.32 | ― | 0.82% | 11.41% | 16.62% | |
60 Neutral | ₹695.46B | 38.61 | ― | 0.24% | 32.94% | 138.54% | |
57 Neutral | ₹1.16T | 25.72 | ― | 0.09% | 21.11% | -1.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,451.70
453.40
22.69%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,656.30
621.25
60.02%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,161.00
-93.60
-7.46%
IN:LUPIN
Lupin Limited
2,152.60
215.00
11.10%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,933.00
367.70
23.49%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,151.20
143.76
14.27%
Glenmark Pharmaceuticals Limited Corporate Events
Glenmark Enters $70 Million U.S. Calcium Gluconate Market With New Injectables Launch
Aug 21, 2026
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in three presentations – 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, and a 10,000 mg/100 mL pharmacy bulk package – for the U.S. market. The produ...
Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray
Aug 20, 2026
Glenmark Pharmaceuticals has secured U.S. FDA approval for its Fluticasone Propionate Nasal Spray USP, 0.05 mg per spray, a generic version deemed bioequivalent and therapeutically equivalent to Haleon’s branded Flonase Nasal Spray. The prod...
Glenmark Launches Generic Olanzapine Injection in U.S. Institutional Market
Jul 6, 2026
Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial, a product deemed bioequivalent and therapeutically equivalent to Zyprexa IntraMuscular Injection 10 mg/vial. The reference market for this anti...
Glenmark Advances Global Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer
Jul 2, 2026
Glenmark Specialty S.A., a wholly owned unit of Glenmark Pharmaceuticals, has advanced a multi-country Phase 3 clinical trial of Trastuzumab rezetecan, a HER2-targeted antibody drug conjugate for patients with platinum-resistant ovarian cancer. In...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.